Medical Tidbits, Ongoing clinical study of Tumor Paint BLZ-100 in pediatric brain cancer patients highlighted

clinical trials for cancer

SEATTLE–(BUSINESS WIRE)–Blaze Bioscience, Inc., the Tumor Paint Company®, a biotechnology company focused on guided cancer therapy, announced today that the company’s Senior Vice President of Development, Dennis Miller, Ph.D., will present at the American Society of Surgical Oncology (ASCO) 2016 Annual Meeting, taking place in Chicago, IL on June 3-7, 2016.

“Phase 1 Dose Escalation and Expansion Safety Study of BLZ-100 in Pediatric Subjects with Primary Central Nervous System Tumors”

The poster presentation, titled “Phase 1 Dose Escalation and Expansion Safety Study of BLZ-100 in Pediatric Subjects with Primary Central Nervous System Tumors,” will highlight the company’s first study in the pediatric population. read more

New MenaQ7® Vitamin K2 Study Validates Inflammation Benefits

OSLO, NORWAY and METUCHEN, NJ (May 31, 2016) – Journal of Medicinal Food has published a new study that successfully tested and confirmed the role of vitamin K2 as MK-7 (menaquinone-7; MenaQ7® provided by NattoPharma) in modulation of the immune and inflammatory biomarkers.

The study, Inhibition of TNF-a, IL-1a, and IL-1b by Pretreatment of Human Monocyte-Derived Macrophages with Menaquinone-7 and Cell Activation with TLR Agonists In Vitro ,” is significant because it confirms another mechanism by which vitamin K2 supports cardiovascular health by impact markers of inflammation. read more

Initial results from the ongoing Swedish Phase II study with IdeS in sensitized kidney transplant patients will be presented at TTS 2016

Dr. Tomas Lorant, principal investigator, will present data from the ongoing Swedish Phase II study with IdeS in sensitized kidney transplant patients at the 26thInternational Congress of the Transplantation Society in Hong Kong in August 2016. The meeting abstract published ahead of the presentation includes preliminary data from 6 transplanted patients with HLA antibodies in the on-going Phase II study.  read more

European Commission Approves IMBRUVICA® (ibrutinib) for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia

NORTH CHICAGO, Ill., May 31, 2016 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the European Commission (EC) approved IMBRUVICA® (ibrutinib) as a first-line treatment option for adult patients with chronic lymphocytic leukemia (CLL), expanding upon the initial ECapproval in October 2014 for certain patients with CLL. This decision comes just one month after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued an opinion in favor of the use of IMBRUVICA for the treatment of adult patients with first-line chronic lymphocytic leukemia (CLL) in the European Union (EU). read more

BioVentrix receives FDA IDE Approval for its Pivotal Clinical Trial, ALIVE

SAN RAMON, Calif., May 31, 2016 /PRNewswire/ — BioVentrix Inc., an emerging medical device company for less invasive treatment of heart failure (HF), today announced that it has received a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial, named ALIVE (American Less Invasive Ventricular Enhancement).  The trial is designed to demonstrate the safety and effectiveness of the Revivent TC™ TransCatheter Ventricular Enhancement System; a hybrid closed-chest transcatheter procedure to treat patients suffering from ischemic cardiomyopathy by reshaping and restoring the left ventricle (LV).  This is accomplished by implanting micro-anchoring pairs in the LV to exclude scarred myocardium from the healthy tissue. read more

EQT VI sells Atos Medical to PAI Europe VI

  • EQT VI sells Atos Medical, the global medical technology leader in laryngectomy care, to PAI Europe VI
  • Atos Medical manufactures and sells a range of products that help patients who have undergone total laryngectomy to restore their ability to speak and increase their quality of life
  • Under the ownership of EQT VI, Atos Medical has almost doubled its size, driven by significant sales force investments, new innovative product introductions and a new direct-to-consumer sales model

Pixium Vision Receives Clinical Trial Approval From UK Regulatory Authority for 150 Electrode IRIS®II Bionic Vision System

PARIS–(BUSINESS WIRE)–Pixium Vision (Paris:PIX) (FR0011950641 – PIX), a company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, today announced that it has received approval from the Medicines & Healthcare products Regulatory Agency (MHRA) in the UK to initiate a clinical trial for patients who have lost sight due to retinitis pigmentosa (RP) with the IRIS® II bionic vision system. This system being evaluated includes a mini bio-inspired camera and a 150 electrode epi-retinal implant with an explantable design. read more

Janssen’s IMBRUVICA®▼(ibrutinib) Approved by European Commission for Patients with Newly Diagnosed Chronic Lymphocytic Leukaemia

Commission (EC) has approved IMBRUVICA® (ibrutinib) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).1 This broadens the indication beyond the initial CLL approval by the EC in October 2014. Ibrutinib is now approved for all patients with CLL, expanding the number of patients who may benefit from this more

Boehringer Ingelheim and Inventiva collaborate to develop potential new treatments for idiopathic pulmonary fibrosis

INGELHEIM, Germany & DAIX, France–(EON: Enhanced Online News)–Boehringer Ingelheim and Inventiva, a French biopharmaceutical company specialised in the development of innovative therapies for fibrosis, oncology and orphan diseases, announced today, a new multi-year research and drug discovery collaboration and licensing agreement. read more

CollPlant Receives Chief Scientist’s Authorization for a NIS 12 Million Research and Development Projects with Funding of Approximately 50%

NESS ZIONA, Israel, May 31, 2016 /PRNewswire/ — CollPlant Ltd. (TASE: CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products – announces that it has received authorization from the Chief Scientist of Israel’s Ministry of Economy, for funding approximately 50% of its NIS 12 million development project for 2016. The Chief Scientist’s grant amount to NIS 5.6 million, measurably higher than last year’s authorized grant, which totaled NIS 4.7 million.  read more


Med Career News Medical Tidbits

Subscribe today for leading medical news and career advice from top medical recruiters!

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.